GNPX
Genprex, Inc.Congress Trades
| Name | Value | Action | Amount Range | Price | Current Price |
|---|---|---|---|---|---|
Tim MooreRepublican $8.0k BuyFeb 5, 2026 $1k-$15k -- -- | |||||
Tim MooreRepublican $8.0k3.7k shares BuyDec 18, 2025 $1k-$15k $2.17 -- | |||||
Tim MooreRepublican $8.0k1.9k shares BuyNov 7, 2025 $1k-$15k $4.21 -- | |||||
Insider Trades
| Name | Value | Action | Price | Current Price |
|---|---|---|---|---|
Longnecker Brent MDirector $1210 shares SellApr 14, 2026 $1.23 -- | ||||
Longnecker Brent MDirector $108 shares SellApr 14, 2026 $1.23 -- | ||||
News
prnewswire.comPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meetingprnewswire.comMay 26
prnewswire.comGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meetingprnewswire.comMay 14
prnewswire.comGenprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancerprnewswire.comApr 30
prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meetingprnewswire.comApr 28
prnewswire.comPositive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meetingprnewswire.comApr 22